


Determining Effect of Postoperative Transcutaneous Electrical Acupoint Stimulation on Recovery Quality After Gynecological Laparoscopic Surgery [Letter]

Zhi-Bin Huang¹, Yong-Bao Lin¹, Fu-Shan Xue^{1,2} 

¹Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou, People's Republic of China; ²Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, People's Republic of China

Correspondence: Fu-Shan Xue, Email xuefushan@aliyun.com; fushanxue@outlook.com

Dear editor

By performing a randomized controlled trial in a total of 97 female participants who underwent elective gynecological laparoscopic surgery under general anesthesia, Zhou et al¹ demonstrated that a 30-min transcutaneous electrical acupoint stimulation (TEAS) in the immediate post-anesthesia recovery period produced an improved quality of postoperative recovery assessed by the 15-item quality of recovery questionnaire (QoR-15). However, as a randomized controlled trial, we noticed several issues about the methods and results of this study that need further discussion and clarifications.

First, the main aim of this study was to evaluate the effect of postoperative TEAS intervention on the recovery quality after gynecological surgery. Zhou et al¹ did not state if the two groups were comparable with respect to preoperative comorbidities, nutritional status, hemoglobin and serum protein levels, psychological and sleep disorders, though they are routine screening parameters. Available literatures indicate that preoperative comorbidities including diabetes and lung disease, frailty, malnutrition, hypoalbuminemia, anemia, sleep disorders, depression and anxiety are significantly associated with increased risks of complications and delayed recovery after gynecological laparoscopic surgery.^{2,3} We are concerned that any significant between-group difference in these unknown preoperative factors would have biased the main findings of this study.

Second, postoperative analgesia scheme only included intravenous tramadol as needed. This is not in agreement with the opioid-sparing multimodal analgesia scheme recommended by the current enhanced recovery after gynecologic surgery practice, which emphasizes a combined use of analgesics with different mechanisms, especially scheduled administration of non-opioid analgesics, such as acetaminophen, non-steroidal anti-inflammatory drugs, ketamine, dexamethasone and others. Given that opioid-associated adverse events can worsen patient experience and delay postoperative functional recovery, minimizing or avoiding opioid use by the opioid-sparing multimodal analgesia pathway has been recommended to improve patient experience and enhance functional recovery after surgery.³ Thus, we argue that the different results about the quality of postoperative recovery would have obtained if an opioid-sparing multimodal analgesia scheme had been included in this study design.

Finally, the QoR-15 score measured 24 h postoperatively was significantly improved with postoperative TEAS, but the net between-group difference of mean global QoR-15 scores 24 h postoperatively only was 4.38 points, which is less than the recommended minimal clinically important difference, that is, a 6-point difference.⁴ Furthermore, as the QoR-15 score measured 24 h postoperatively cannot provide a true evaluation of postoperative recovery quality, it is often required that a repeated measurement of QoR-15 score 48 h postoperatively should be conducted to enable an adequate evaluation of postoperative recovery quality.⁵ In this study, however, mean global QoR-15 scores 48 h postoperatively were not statistically significant between groups. Similarly, the time to first flatus was significantly reduced with postoperative TEAS, but its net between-group difference was 1.78 h, which does also not exceed the recommended

minimal clinically important difference, that is, a 6-h difference.⁶ Thus, we question the real clinical significance of improved postoperative function recovery with postoperative TEAS in patients undergoing gynecological laparoscopic surgery. We completely agree with the authors' opinion that future large-scale clinical trials with rigorous design are still needed to validate the results of this study.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Zhou Z, Yang X, Shi M, et al. Efficacy of transcutaneous electrical acupoint stimulation applied during the post-anesthesia recovery period in improving postoperative recovery quality after gynecological laparoscopic surgery: a randomized controlled trial. *Ther Clin Risk Manag.* 2025;21:1175–1186. doi:10.2147/TCRM.S507856
2. Chao L, Lin E, Kho K. Enhanced recovery after surgery in minimally invasive gynecologic surgery. *Obstet Gynecol Clin North Am.* 2022;49(2):381–395. doi:10.1016/j.ogc.2022.02.014
3. Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update. *Int J Gynecol Cancer.* 2019;29(4):651–668. doi:10.1136/ijgc-2019-000356
4. Myles PS, Myles DB. An updated minimal clinically important difference for the QoR-15 scale. *Anesthesiology.* 2021;135(5):934–935. doi:10.1097/ALN.0000000000003977
5. Chazapis M, Walker EM, Rooms MA, Kamming D, Moonesinghe SR. Measuring quality of recovery-15 after day case surgery. *Br J Anaesth.* 2016;16(2):241–248. doi:10.1093/bja/aev413
6. Doleman B, Leonardi-Bee J, Heinink TP, et al. Pre-emptive and preventive NSAIDs for postoperative pain in adults undergoing all types of surgery. *Cochrane Database Syst Rev.* 2021;6(6):CD012978. doi:10.1002/14651858.CD012978

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Therapeutics and Clinical Risk Management 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Therapeutics and Clinical Risk Management editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Therapeutics and Clinical Risk Management

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

<https://doi.org/10.2147/TCRM.S559827>